Please assess the completion status of the following clinical trial:

Trial Title: Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults age 18-100 years with Rutherford Classification Stage IV through VI PAD with a recent percutaneous lower extremity arterial angiography with arterial intervention in the past 2 weeks~2. Willingness to sign informed consent~3. Ability to return for follow up visits~4. A female patient of childbearing potential who is sexually active must agree to use adequate contraception from screening until 30 days after receiving the last dose of study drug. Women not of childbearing potential are defined as those who have surgically sterilized (hysterectomy, bilateral oophorectomy, or tubal ligation) or who are post menopausal (defined as at least 2 years since last regular menses). The female patient should not be lactating and must have a negative pregnancy test at screening.~Exclusion Criteria:~Patients will be ineligible for this study if they meet any one of the following criteria:~1. Intolerance to thienopyridines~2. Hypersensitivity to ticagrelor or any component of the product.~3. Concomitant use of oral anticoagulation with vitamin K antagonist, factor Xa inhibitor, or direct thrombin inhibitor~4. History of intracranial hemorrhage~5. History of severe hepatic impairment defined by baseline transaminase greater than or equal to 3x ULN or any elevation in bilirubin~6. Active bleeding~7. Allergy to aspirin~8. Baseline TcPO2 \< 10 mmHg post angiography~9. Resting, pre- procedure heart rate \<50 beats-per-minute without a permanent pacemaker and not on an atrioventricular nodal blocking agent~10. Severe COPD on home oxygen therapy -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel 75mg by mouth daily
- Ticagrelor (Type: EXPERIMENTAL): Ticagrelor 90mg by mouth twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).